Human Genome Epidemiology Literature Finder
|
Records 1 - 30 (of 49 Records) |
| Query Trace: Sarcoma and Alk[original query] |
|---|
| Efficacy of Pemetrexed-Based Chemotherapy in Patients with ROS1 Fusion-Positive Lung Adenocarcinoma Compared with in Patients Harboring Other Driver Mutations in East Asian Populations. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2016 Apr . Chen Yen-Fu, Hsieh Min-Shu, Wu Shang-Gin, Chang Yih-Leong, Yu Chong-Jen, Yang James Chih-Hsin, Yang Pan-Chyr, Shih Jin-Yu |
| EGFR, ALK, RET, KRAS and BRAF alterations in never-smokers with non-small cell lung cancer. Oncology letters 2016 Apr 11 (4): 2371-2378. Dong Y U, Ren Weihong, Qi Jun, Jin B O, Li Ying, Tao Huiqing, Xu Ren, Li Yanqing, Zhang Qinxian, Han Baoh |
| Phase II Study of a Non-Platinum-Containing Doublet of Paclitaxel and Pemetrexed with Bevacizumab as Initial Therapy for Patients with Advanced Lung Adenocarcinomas. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2016 Mar . Pietanza Catherine M, Hellmann Matthew D, Fiore John J, Smith-Marrone Stephanie, Basch Ethan M, Schwartz Lawrence H, Ginsberg Michelle S, Shouery Marwan, Newman Samantha K, Shaw Mary, Rogak Lauren J, Lash Alex, Hilden Patrick, Kris Mark |
| Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma. European journal of cancer (Oxford, England : 1990) 2016 Feb 57 91-103. Yang Ching-Yao, Lin Mong-Wei, Chang Yih-Leong, Wu Chen-Tu, Yang Pan-Ch |
| The expression of SALL4 is significantly associated with EGFR, but not KRAS or EML4-ALK mutations in lung cancer. Journal of thoracic disease 2016 Oct 8 (10): 2682-2688. Jia Xiangbo, Qian Rulin, Zhang Binbin, Zhao So |
| Survival difference according to mutation status in a prospective cohort study of Australian patients with metastatic non-small-cell lung carcinoma. Internal medicine journal 2018 01 48 (1): 37-44. Tan Lavinia, Alexander Marliese, Officer Ann, MacManus Michael, Mileshkin Linda, Jennens Ross, Herath Dishan, de Boer Richard, Fox Stephen B, Ball David, Solomon Benjam |
| Unique prevalence of oncogenic genetic alterations in young patients with lung adenocarcinoma. Cancer 2017 Feb . Tanaka Kosuke, Hida Toyoaki, Oya Yuko, Yoshida Tatsuya, Shimizu Junichi, Mizuno Tetsuya, Kuroda Hiroaki, Sakakura Noriaki, Yoshimura Kenichi, Horio Yoshitsugu, Sakao Yukinori, Yatabe Yasus |
| Population-level effect of molecular testing and targeted therapy in patients with advanced pulmonary adenocarcinoma: a prospective cohort study. Virchows Archiv : an international journal of pathology 2018 Apr 472 (4): 581-588. Schwegler Christine, Kaufmann Dinu, Pfeiffer David, Aebi Stefan, Diebold Joachim, Gautschi Oliv |
| [Association between the ALK Gene Status and the Efficacy of First-line ?Pemetrexed Chemotherapy in Patients with Advanced Lung Adenocarcinoma]. Zhongguo fei ai za zhi = Chinese journal of lung cancer 2017 11 20 (11): 732-736. Chen Mengge, Cao Hui, Ji Yingying, Mao Yuhuan, Shen Shujing, Li Xing |
| Identification of genome variations in patients with lung adenocarcinoma using whole genome re?sequencing. Molecular medicine reports 2017 10 16 (6): 9464-9472. Li Guiyuan, Mei Yunqing, Yang Fan, Yi Shengming, Wang Lem |
| [Gene Expression and Clinical Characteristics of Molecular Targeted Therapy ?in Non-small Cell Lung Cancer Patients in Shandong]. Zhongguo fei ai za zhi = Chinese journal of lung cancer 2017 Jan 20 (1): 14-20. Qiao Xiuli, Ai Dan, Liang Honglu, Mu Dianbin, Guo Qis |
| Detection of RAS and RAS-associated alterations in primary lung adenocarcinomas. A correlation between molecular findings and tumor characteristics. Human pathology 2018 Sep . Shaukat Irfan, Kern Jason J, Höti Naseruddin, Zhang Hui, Li Jason, Zheng Gang, Askin Frederic, Gabrielson Edward, Li Qing K |
| MET Expression in Advanced Non-Small-Cell Lung Cancer: Effect on Clinical Outcomes of Chemotherapy, Targeted Therapy, and Immunotherapy. Clinical lung cancer 2018 07 19 (4): e441-e463. Reis Henning, Metzenmacher Martin, Goetz Moritz, Savvidou Nikoleta, Darwiche Kaid, Aigner Clemens, Herold Thomas, Eberhardt Wilfried E, Skiba Charlotte, Hense Jörg, Virchow Isabel, Westerwick Daniela, Bogner Simon, Ting Saskia, Kasper Stefan, Stuschke Martin, Nensa Felix, Herrmann Ken, Hager Thomas, Schmid Kurt W, Schuler Martin, Wiesweg Marc |
| Aberrant status and clinicopathologic characteristic associations of 11 target genes in 1,321 Chinese patients with lung adenocarcinoma. Journal of thoracic disease 2018 Jan 10 (1): 398-407. Zhao Mengnan, Zhan Cheng, Li Ming, Yang Xiaodong, Yang Xinyu, Zhang Yong, Lin Miao, Xia Yifeng, Feng Mingxiang, Wang Q |
| Quantitative features of dual-energy spectral computed tomography for solid lung adenocarcinoma with EGFR and KRAS mutations, and ALK rearrangement: a preliminary study. Translational lung cancer research 2019 9 8 (4): 401-412. Li Meng, Zhang Li, Tang Wei, Ma Pei-Qing, Zhou Li-Na, Jin Yu-Jing, Qi Lin-Lin, Wu Ni |
| Genotyping and cytomorphological subtyping of lung adenocarcinoma based on liquid-based cytology. Diagnostic cytopathology 2019 Feb . Tanaka Ryota, Sakamoto Norihiko, Suzuki Hitomi, Tachibana Keisei, Ohtsuka Kouki, Kishimoto Koji, Fujiwara Masachika, Kamma Hiroshi, Shibahara Junji, Kondo Haruhi |
| Association of ALK rearrangement and risk of venous thromboembolism in patients with non-small cell lung cancer: A prospective cohort study. Thrombosis research 2019 Dec 186 36-41. Dou Feifei, Zhang Yuan, Yi Jiawen, Zhu Min, Zhang Shu, Zhang Di, Zhang Yuh |
| Comparison of Clinicopathological Features and Prognosis between ALK Rearrangements and EGFR Mutations in Surgically Resected Early-stage Lung Adenocarcinoma. Journal of Cancer 2019 10 (1): 61-71. Li Pupu, Gao Qiongqiong, Jiang Xiangli, Zhan Zhongli, Yan Qingna, Li Zhaona, Huang Ch |
| Cytology of SMARCA4-Deficient Thoracic Neoplasms: Comparative Analysis of SMARCA4-Deficient Non-Small Cell Lung Carcinomas and SMARCA4-Deficient Thoracic Sarcomas. Acta cytologica 2020 8 65 (1): 67-74. Nambirajan Aruna, Dutta Rimlee, Malik Prabhat Singh, Bubendorf Lukas, Jain Deepa |
| [Analysis of Clinical Characteristics and Driver Genes in 405 Patients with Lung Cancer Complicated with Tuberculosis]. Zhongguo fei ai za zhi = Chinese journal of lung cancer 2020 4 23 (5): 337-342. Hu Ying, Yang Xinjie, Nie Lihui, Zhao Dan, An Jun, Li Baol |
| [Genetic Profile of Young Chinese Patients with Lung Adenocarcinoma]. Zhongguo fei ai za zhi = Chinese journal of lung cancer 2020 Apr 23 (4): 239-246. Liang Yu, Hou Helei, Jiang Man, Zhang Chuantao, Liu Dong, Zhang Xiaoch |
| Pathologic complete response to preoperative immunotherapy in a lung adenocarcinoma patient with bone metastasis: A case report. Thoracic cancer 2020 2 11 (4): 1094-1098. Tang Yong, Li Yadan, Zhang Lei, Tong Guihui, Ou Zhu'an, Wang Zhuocai, Zhang Henghui, Qiao Guib |
| Chronic Plasma Exposure to Kinase Inhibitors in Patients with Oncogene-Addicted Non-Small Cell Lung Cancer. Cancers 2020 12 12 (12): . Geraud Arthur, Mezquita Laura, Auclin Edouard, Combarel David, Delahousse Julia, Gougis Paul, Massard Christophe, Jovelet Cécile, Caramella Caroline, Adam Julien, Naltet Charles, Lavaud Pernelle, Gazzah Anas, Lacroix Ludovic, Rouleau Etienne, Vasseur Damien, Mir Olivier, Planchard David, Paci Angelo, Besse Benjam |
| Integration of clinicopathological and mutational data offers insight into lung cancer with tumor spread through air spaces. Annals of translational medicine 2021 Jun 9 (12): 985. Tian Yu, Feng Jing, Jiang Long, Ning Junwei, Gu Zenan, Huang Jia, Luo Qingqu |
| Profiling Oncogenic Germline Mutations in Unselected Chinese Lung Cancer Patients. Frontiers in oncology 2021 4 11 647598. Yang Jie, Li Hefei, Li Ben, Li Wei, Guo Qiang, Hu Ling, Song Zizheng, Zhou B |
| Concomitant mutation status of ALK-rearranged non-small cell lung cancers and its prognostic impact on patients treated with crizotinib. Translational lung cancer research 2021 4 10 (3): 1525-1535. Li Jingjing, Zhang Bin, Zhang Yu, Xu Feng, Zhang Zhenfa, Shao Lin, Yan Chunhe, Ulivi Paola, Denis Marc G, Christopoulos Petros, Thomas de Montpréville Vincent, Bernicker Eric H, van der Wekken Anthonie J, Wang Changli, Yue Dongshe |
| Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ?50%: real-world data. Oncoimmunology 2021 2 10 (1): 1865653. Dudnik Elizabeth, Moskovitz Mor, Rottenberg Yakir, Lobachov Anastasiya, Mandelboim Rinat, Shochat Tzippy, Urban Damien, Wollner Mira, Nechushtan Hovav, Rotem Ofer, Zer Alona, Daher Sameh, Bar Jair, |
| Prognosis and oncogenomic profiling of patients with tropomyosin receptor kinase fusion cancer in the 100,000 genomes project. Cancer treatment and research communications 2022 Aug 33 100623. Bridgewater John, Jiao Xiaolong, Parimi Mounika, Flach Clare, Stratford Jeran, Kamburov Atanas, Schmitz Arndt A, Zong Jihong, Reeves John A, Keating Karen, Bruno Amanda, Fellous Marc, Pereira Mariana Buongermino, Bazhenova Lyudmi |
| Computed tomography-guided lung biopsy for molecular tests: a meta-analysis. Kardiochirurgia i torakochirurgia polska = Polish journal of cardio-thoracic surgery 2022 Jun 19 (2): 96-101. Zhang Jian-Hua, Xia Feng-Fei, Yang Xiao-Shan, Li |
| Correlation between Programmed Death Ligand-1(PD-L1) Expression and Driver Gene Mutations in Non-Small Cell Lung Carcinoma- Adenocarcinoma Phenotype. Asian Pacific journal of cancer prevention : APJCP 2022 Jan 23 (1): 131-142. Pandey Rahul Kumar, Shukla Saumya, Husain Nuzhat, Islam Mohammad Hayatul, Hadi Rahat, Kant Tripathi Surya, Singhal Ashi |
- Page last reviewed:Feb 1, 2024
- Content source: